HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

remestemcel-l

Also Known As:

JR 0301; Prochymal; remestemcel

Networked: 17 relevant articles (2 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - remestemcel-l: 17
Cells
- Connective Tissue Cells
  - Stromal Cells
    - Mesenchymal Stem Cells
      - remestemcel-l: 17
- Stem Cells
  - Multipotent Stem Cells
    - Mesenchymal Stem Cells
      - remestemcel-l: 17

Experts

1.	Hayes, Jack: 4 articles (05/2021 - 01/2020)
2.	Burke, Elizabeth: 4 articles (01/2021 - 01/2020)
3.	Chaudhury, Sonali: 3 articles (01/2020 - 02/2014)
4.	Horn, Biljana: 3 articles (01/2020 - 02/2014)
5.	Kurtzberg, Joanne: 3 articles (01/2020 - 02/2014)
6.	Nemecek, Eneida: 3 articles (01/2020 - 02/2014)
7.	Prockop, Susan: 3 articles (01/2020 - 02/2014)
8.	Fulmer, Clifton: 2 articles (11/2022 - 01/2022)
9.	Lightner, Amy L: 2 articles (11/2022 - 01/2022)
10.	Nachand, Douglas: 2 articles (11/2022 - 01/2022)

Related Diseases

1.	Muscle Weakness 02/23/2021 - "Remestemcel-L-rknd was also associated with improved safety outcomes (P<0.05) in 17 out of 30 AEs, including hematologic events, peripheral edema, muscular weakness, nausea, back pain, and fatigue. "
2.	Nausea 02/23/2021 - "Remestemcel-L-rknd was also associated with improved safety outcomes (P<0.05) in 17 out of 30 AEs, including hematologic events, peripheral edema, muscular weakness, nausea, back pain, and fatigue. "
3.	Inflammation (Inflammations) 01/01/2021 - "When treated with two intravenous doses of remestemcel-L separated by 48 hours, rapid normalization of left ventricular ejection fraction, notable reductions in biomarkers of systemic and cardiac inflammation, and improved clinical status occurred. "
4.	Fatigue 02/23/2021 - "Remestemcel-L-rknd was also associated with improved safety outcomes (P<0.05) in 17 out of 30 AEs, including hematologic events, peripheral edema, muscular weakness, nausea, back pain, and fatigue. "
5.	Edema (Dropsy) 02/23/2021 - "Remestemcel-L-rknd was also associated with improved safety outcomes (P<0.05) in 17 out of 30 AEs, including hematologic events, peripheral edema, muscular weakness, nausea, back pain, and fatigue. "

Related Drugs and Biologics

1.	Biomarkers (Surrogate Marker)
2.	Steroids
3.	remestemcel-l
4.	ruxolitinib

Related Therapies and Procedures

1.	Therapeutics